Keyword Search
 
2018 | 2017 | 2016 | 2015
Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections
August 14, 2018
PDUFA action date set for February 13, 2019 NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for iclaprim, a targeted, Gram-positive investigational antibiotic, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). This means tha... Read More
Motif Bio to Present at Investor Events in August and September
August 9, 2018
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will participate at the following investor events in August and September. 8th Annual Solebury Trout Hamptons CEO Roundtable August 16, 2018 Bridgehampton, NY Graham Lumsden, Chief Executive Officer, will make a presentation on the Company and its product candidate, iclaprim, for whi... Read More
Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037
August 8, 2018
NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office for United States Patent Application Nos. 15/586,021 and 15/586,815.  The claims relate to the use of iclaprim to treat patients with bacterial infections, including but not limited... Read More
Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors
July 3, 2018
NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has informed the Company of his decision to resign from the Board of Directors, effective July 16, 2018. Graham Lumsden, Chief Executive Officer of Motif Bio, said: “On behalf of the Board, we are grateful to Bob for his dedication and service to the company since its inception.  We h... Read More
Result of Annual General Meeting
June 19, 2018
NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual General Meeting held earlier today, all resolutions proposed were duly passed by the shareholders on a poll. The results of the poll, incorporating the proxy votes lodged in advance of the meeting, will shortly be available on the Company's website at: https://www.motifbio.com/. The full tex... Read More
Motif Bio Submits NDA for Iclaprim
June 14, 2018
NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for iclaprim, a targeted, Gram-positive investigational antibiotic, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). “The NDA submission for iclaprim i... Read More
Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018
June 11, 2018
Pooled efficacy and safety data from REVIVE Phase 3 trials presented Data also published in peer-reviewed journal, International Journal of Antimicrobial Agents NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that the pooled efficacy and safety data from its two Phase 3 trials (REVIVE-1 and REVIVE-2) in patients with acute bacterial skin and skin struct... Read More
Motif Bio to present at Jefferies Global Healthcare Conference in New York
May 31, 2018
NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will give a company presentation and meet with investors at the following event: Jefferies Global Healthcare Conference June 5-8, 2018 New York, NY USA Graham Lumsden, Chief Executive Officer, will give a company presentation on June 8th at 10:30 AM ET. The presentation will be webcast,... Read More
Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development
May 9, 2018
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Stephanie Noviello, MD, MPH has joined the Company as Vice President, Clinical Development.  She will report to David Huang, MD, PhD, Chief Medical Officer.  Dr. Noviello will be a key contributor to the European Marketing Authorisation Application submission for iclaprim. Dr. Noviello joins Motif Bio... Read More
Motif Bio to Present Iclaprim Data at ASM Microbe 2018
May 8, 2018
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that two iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microbiology (ASM) Microbe 2018 meeting to be held in Atlanta, GA, USA, June 7-11, 2018.  The abstracts are now available online on the ASM website. ASM Microbe showcases the best microbial sciences in the ... Read More
Motif Bio REVIVE-2 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Antimicrobial Agents and Chemotherapy
May 1, 2018
Iclaprim met the primary endpoint Iclaprim was well tolerated in the study, with no nephrotoxicity observed Additional data from the previously announced results are included in the publication NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the results from REVIVE-2, a global Phase 3 clinical trial evaluating the investigational drug cand... Read More
Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018
April 19, 2018
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSI Potential to avoid costs related to vancomycin-associated acute kidney injury in ABSSSI Data continue to support iclaprim activity against MRSA and other drug-resistant pathogens Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that new clinical and pre-clinical data w... Read More
Posting of UK Annual Report and Accounts & Notice of AGM
April 17, 2018
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its 2017 UK Annual Report and Accounts and notice of its Annual General Meeting have been posted to shareholders and will shortly be available for download from the Company's website at www.motifbio.com. This follows the announcement made by the Company on 10 April 2018 via RNS of the publication of i... Read More
Motif Bio Announces Iclaprim Abstracts for ECCMID 2018 Now Online
April 11, 2018
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that iclaprim-related abstracts are now online for the upcoming 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) to be held in Madrid, Spain, April 21-24, 2018. The abstracts are as follows: A phase-3, randomized, double-blind, multicentre study to evaluate the safety ... Read More
Motif Bio Reports Fiscal Year 2017 Results
April 10, 2018
NEW YORK, April 10, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2017. Dr. Graham Lumsden, Chief Executive Officer, said:  “Motif Bio made tremendous progress in 2017, accomplishing several critical milestones, including announcing positive topline results from two Phase 3 clinical trials with iclaprim in acute bacteri... Read More
Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update
April 3, 2018
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the initiation of a rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for iclaprim, a targeted, Gram-positive investigational antibiotic, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The NDA submission is expected to be c... Read More
Motif Bio Update on NDA Submission for Iclaprim
March 20, 2018
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today provided an update on the status and timeline for submission of its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its targeted, Gram-positive investigational antibiotic, iclaprim, for the treatment of acute bacterial skin and skin structure infections (ABSSSI). In consultation with i... Read More
Motif Bio to present at upcoming investor and scientific conferences
March 19, 2018
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company will present at the following conferences in March. Superbugs & Superdrugs 2018 March 19-20, 2018 London, UK David Huang, MD, PhD, Chief Medical Officer, will give a presentation on iclaprim at 12:10 PM on Tuesday, March 20th.  This event gathers leaders from pharmaceutical companies, ... Read More
Motif Bio to Present Iclaprim Data at ECCMID 2018
February 21, 2018
Phase 3 trial results for REVIVE-2 in patients with ABSSSI Potential cost savings opportunities with iclaprim versus vancomycin Iclaprim in vitro susceptibility data NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that three iclaprim abstracts have been accepted for presentation at the upcoming 28th European Congress of Clinical Microbiology and Inf... Read More
Appointment of Jonathan E. Gold as Interim Chief Financial Officer
February 2, 2018
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Dickey IV has informed the Company of his intention to resign from his role as Chief Financial Officer (CFO).  A search process for a new CFO has commenced and Jonathan E. Gold, currently a Non-executive Director of the Company, has agreed to serve as interim CFO.  ... Read More
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
January 29, 2018
WASHINGTON, Jan. 29, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Sp... Read More
Motif Bio Announces Filing of U.S. Shelf Registration
January 19, 2018
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio® plc (AIM/NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has filed a “universal” shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (the “SEC”). The filing of a shelf registration statement, a common practice by NASDAQ-listed companies, is intended to provide the Company with more timely and efficient access to the... Read More
Motif Bio Receives Award from Cystic Fibrosis Foundation
January 16, 2018
NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Motif Bio® plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received an award from the Cystic Fibrosis Foundation to fund important in vitro testing that will help to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis (CF). This is the first award that the Company has received from the Cysti... Read More
Motif Bio to participate in panel discussion at upcoming Cantor Antibiotics Summit
January 5, 2018
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will participate in the following event: Cantor Antibiotics Summit January 17, 2018 Omni Berkshire Hotel New York, NY USA Graham Lumsden, Chief Executive Officer, will participate in a panel discussion, “Catalysts to Look for in 2018.” The Cantor Antibiotics Summit will bring togethe... Read More